Clinical profile and predictors of biochemical markers of metabolic bone disease in very preterm neonates: An observational study
- 20 November 2025
- journal article
- Published by SAGE Publications in Tropical Doctor
- Vol. 56 (2) , 284-287
Abstract
Metabolic bone disease (MBD) is a significant concern in very preterm neonates, with clinical signs often delayed compared to biochemical and radiological markers. MBD was defined as serum phosphate 600 IU/L or alkaline phosphatase >1000 IU/L. Key risk factors included lower gestational age, lower birth weight, prolonged total parenteral nutrition, delayed attainment of full enteral feeding (>7 days), cholestasis, bronchopulmonary dysplasia, and anaemia requiring transfusion. Logistic regression identified delayed attainment of full enteral feeding (>7 days) as a significant predictor for developing MBD.Keywords
This publication has 6 references indexed in Scilit:
- Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequencesArchives of Disease in Childhood - Fetal and Neonatal Edition, 2019
- Metabolic bone disease in the preterm infant: Current state and future directionsWorld Journal of Methodology, 2015
- Metabolic bone disease of prematurityJournal of Clinical & Translational Endocrinology, 2014
- Bone Development in the Fetus and Neonate: Role of the Calciotropic HormonesCurrent Osteoporosis Reports, 2011
- High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional supportBMC Pediatrics, 2009
- Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurityActa Paediatrica, 2000